Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) is a clinical-stage biopharmaceutical company that reports frequent updates related to its work in genetically defined rare diseases. Company news regularly highlights progress for its lead program, pociredir, an investigational oral small molecule designed to increase fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD).
Investors and followers of FULC can expect news items covering clinical trial milestones, such as initial and updated data from the Phase 1b PIONEER trial of pociredir in adults with severe SCD. Fulcrum’s releases describe dose-escalation cohorts, changes in HbF levels, markers of hemolysis and anemia, and observations related to vaso-occlusive crises, along with safety and tolerability findings.
Fulcrum also issues corporate and financial announcements, including quarterly financial results, cash runway commentary, and details of public offerings of common stock and pre-funded warrants. Additional news may feature participation in major medical and investor conferences, such as the American Society of Hematology Annual Meeting and the J.P. Morgan Healthcare Conference, where the company presents clinical and preclinical data.
Other updates include disclosures on early-stage programs, such as calmodulin pathway modulators for bone marrow failure syndromes and preclinical data for EED inhibitor candidates in oncology models, as well as routine items like inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). For readers tracking FULC, this news stream provides insight into the evolution of Fulcrum’s pipeline, its clinical development strategy in sickle cell disease, and its broader efforts in gene-expression modulation for rare diseases.
Fulcrum Therapeutics (NASDAQ: FULC) announced results from its Phase 2b ReDUX4 trial of losmapimod for facioscapulohumeral muscular dystrophy (FSHD). While the primary endpoint of DUX4-driven gene expression was not met, significant clinical benefits were observed, including reduced muscle fat infiltration and improved functional outcomes. Losmapimod was well tolerated, with no serious adverse events related to treatment. The company plans to engage with the FDA regarding future regulatory steps in H2 2021. Overall, these results support losmapimod as a potential transformative therapy for FSHD.
Fulcrum Therapeutics (Nasdaq: FULC) will hold a conference call on June 24, 2021, at 8:00 am ET to discuss the results of the Phase 2b ReDUX4 trial involving losmapimod for treating facioscapulohumeral muscular dystrophy (FSHD). The company is presenting multiple findings at the 28th Annual FSHD Society International Research Congress. These include efficacy and safety data from the trial. FSHD affects 16,000 to 38,000 patients in the U.S., with no approved treatments available. Losmapimod has received FDA Fast Track designation.
Fulcrum Therapeutics (Nasdaq: FULC) has received Fast Track designation from the FDA for losmapimod, aimed at treating facioscapulohumeral muscular dystrophy (FSHD), a disease with no approved therapies. This designation assists in expedited drug development and review. Recent Phase 2b trial data from ReDUX4 will be reported at the FSHD International Research Congress on June 24-25, 2021. Losmapimod, previously granted Orphan Drug Designation, has been evaluated in over 3,600 subjects without safety signals reported.
Fulcrum Therapeutics (Nasdaq: FULC) announced its participation in the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 11:00 a.m. ET. The presentation will provide a corporate overview of the company, which focuses on genetically defined rare diseases. Investors can access a live audio webcast on Fulcrum's Investor Relations website, with an archived replay available for 90 days. The company is advancing treatments for conditions like facioscapulohumeral muscular dystrophy and sickle cell disease.
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) reported first quarter 2021 financial results, highlighting a cash position of $143.9 million, sufficient to fund operations into Q4 2022. Collaboration revenue surged to $4.8 million, up from $0.8 million YoY, attributed to partnerships with MyoKardia and Acceleron. Key clinical progress includes upcoming data from the Phase 2b ReDUX4 trial for facioscapulohumeral muscular dystrophy and the Phase 1 trial for sickle cell disease. The company has also appointed new leadership, enhancing its strategic capabilities.
Fulcrum Therapeutics appointed Dr. Christopher J. Morabito as Chief Medical Officer, effective May 10, 2021. Dr. Morabito brings over 20 years of experience in the biotechnology sector, focusing on advancing clinical programs for rare diseases, including facioscapulohumeral dystrophy (FSHD) and hemoglobinopathies such as sickle cell disease. His previous roles include leadership positions at Cardurion Pharmaceuticals and Takeda. The company aims to leverage his expertise to enhance its clinical pipeline and drug development initiatives.
Fulcrum Therapeutics (Nasdaq: FULC) announced that it will release its first quarter 2021 financial results on May 6, 2021, prior to market opening. A conference call and webcast are scheduled for 8:00 a.m. ET to discuss these results and the company's recent developments. Fulcrum is focused on treating genetically defined rare diseases, with its lead product, losmapimod, in Phase 2 clinical trials for facioscapulohumeral dystrophy (FSHD) and FTX-6058 in Phase 1 trials for sickle cell disease and beta-thalassemia.
Fulcrum Therapeutics (Nasdaq: FULC) has initiated dosing in its Phase 1 trial of FTX-6058, an orally bioavailable EED inhibitor targeting hemoglobinopathies like sickle cell disease and β-thalassemia. The trial is assessing the safety, tolerability, and pharmacokinetics of FTX-6058.
Preclinical results indicate a potential increase in fetal hemoglobin (HbF) levels of up to 30%. The company plans to report data from this trial mid-year and initiate a clinical trial in sickle cell patients by the end of 2021.
Fulcrum Therapeutics, a biopharmaceutical firm focused on genetically defined rare diseases, has appointed Dr. Judith A. Dunn as President of Research and Development. Dr. Dunn brings over 25 years of experience in global drug development, previously serving as Vice President at Roche. Her expertise will support Fulcrum's losmapimod and FTX-6058 programs. The company aims to advance these programs, including two INDs in the next 24 months, leveraging its proprietary FulcrumSeek platform for drug target identification.
Fulcrum Therapeutics (Nasdaq: FULC) announced new data on imaging biomarkers and clinical assessments for facioscapulohumeral muscular dystrophy (FSHD) at the 2021 MDA Conference. Whole body musculoskeletal MRI (WB-MSK-MRI) provides vital information on disease severity. FSHD-TUG, a mobility assessment, shows correlation with clinical outcomes. The company is on track to report data from its Phase 2b ReDUX4 trial for losmapimod in late 2Q 2021. This clinical development aims to improve treatment options for FSHD, a condition affecting approximately 16,000 to 38,000 patients in the U.S.